New wireless monitor aims to prevent dangerous low blood sugar in hospitalized veterans

NCT ID NCT03508934

Ongoing Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a wireless glucose monitoring system (Glucose Telemetry System) in 218 hospitalized veterans with type 2 diabetes who are at high risk for low blood sugar (hypoglycemia). The device sends blood sugar readings from the patient's bedside to a monitor at the nursing station, allowing staff to act quickly. The goal is to reduce hypoglycemia episodes, which can cause seizures, heart problems, or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Continuous glucose monitoring device (Glucose Telemetry System)
What this could lead to: If successful, this could provide a safer way to monitor blood sugar in hospitalized patients, reducing the risk of severe hypoglycemia and its complications.
What could go wrong: This is a relatively small, early-stage study focused on a specific population (veterans), so results may not apply to all patients. The device may not significantly reduce hypoglycemia compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 HYPOGLYCEMIA

Contacts and locations

Locations

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.